anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
All subjects are injected with Bee Venom (BV, intervention), randomly assigned to the right or left forearm. Raw BV used dried BV prepared through collection from bee venom sacs and removal of impurities. The BV administration site on each subject was on the palmar side of the designated arm 5 cm below the middle of the elbow crease as it is convenient for observation and has high responsiveness. Pharmacopuncture sessions were also conducted in the morning for higher responsiveness.
The application provides a prediction method of on-machine effect of a mechanical auxiliary device and a cardiovascular model circuit. Firstly, physiological monitoring data of a target object and a preset cardiovascular model can be acquired. The model structure of the preset cardiovascular model is matched with the cardiovascular defect structure of the target object. And then, fitting the preset cardiovascular model by using the physiological monitoring data to obtain a first equivalent cardiovascular model. The structure of the first equivalent cardiovascular model is matched with the model structure of the preset cardiovascular model, and the model structure is used for simulating the blood circulation condition of a target object. Next, input-output characteristic data of the mechanical assist device may be acquired. And then performing on-machine simulation on the target object through the mechanical auxiliary device according to the first equivalent cardiovascular model and the input/output characteristic data so as to obtain physiological simulation data of the target object. Thus, the physiological response of the target object after the machine is started can be predicted according to the physiological simulation data.
The invention relates to a traditional Chinese medicinal composition for improving libido of boar, and belongs to the field of traditional Chinese medicines. Active components of the composition comprises the following active ingredients in parts by weight: 35-45 parts of actinolite, 5-15 parts of fructus psoraleae, 25-35 parts of yam, and 15-25 parts of glossy privet fruit. The traditional Chinese medicinal composition takes yin-nourishing, yang-tonifying, kidney-tonfiying and essence-strengthening as a treatment principle, is reasonable in prescription and simple in preparation process; the traditional Chinese herbal medicinal components are wide in sources and low cost, do not have drug residues, toxic or side effects, and can be easily absorbed by animals. The traditional Chinese medicinal composition has the effects of nourishing yin and tonifying yang, tonifying kidney and strengthening essence, and regulating body mechanism, and can be used for effectively improving the libido of boar and shortening the recovering period. When applied, 0.5g of the composition is dosed for 1kg of the body weight of boar. Clinical tests prove that the cure rate of the composition is over 80 percent, and has a unique curative effect.
PCT No. PCT/EP92/02285 Sec. 371 Date Apr. 20, 1994 Sec. 102(e) Date Apr. 20, 1994 PCT Filed Oct. 2, 1992 PCT Pub. No. WO93/06812 PCT Pub. Date Apr. 15, 1993An emulsion containing one or several polyunsaturated, long-chain omega-3 and/or omega-6 fatty acids or their pharmaceutically tolerable esters or salts, as well as usual adjuvants and additives, is used to produce an intravenously administered medicament for treating skin diseases, in particular inflammatory skin diseases, as well as diseases of the dermatitis or eczema group. Preferably, fatty acids containing 18-22 carbon atoms, as well as their pharmaceutically tolerable esters of salts, are used. These acids or their pharmaceutically tolerable esters or salts may be used in their pure form or as components of oils, such as fish oil, highly-purified fish oil concentrates, linseed oil, primrose oil, borage oil or soya oil. Specially preferred are the pharmaceutically tolerable esters or salts of said acids, in particular the pharmaceutically tolerable esters, especially those derived from eicosapentaenic acid. The emulsions may be further intravenously administered in the framework of a combined therapy with presently known therapies of skin diseases.
Participants will be randomly assigned to the intervention group (50 in total).The VR intervention will be identical for each participant and consist of a PC running the immersive virtual reality application with a Virtual Reality headset 110 degrees field of view head mounted display. The VR will be a set of commercial exploratory virtual environment games designed for the HTC Vive headset. The intervention will be used for one month to enable customization to the therapy and record data over a long enough period of time to account for individual short- term changes in pain experience. Participants will be asked to use the VR therapy every day with a time exposure of 30 minutes for four consecutive weeks. There will be one rest day a week (normally a Sunday) where no therapy is given.
Patients will receive combined immunotherapy in a predefined group. PD-1/PD-L1 inhibitor will be combined with target therapy, such as lenvatinib, enrotinib, herceptin et al.
Peyronie's Disease (PD) is clinically characterized by the development of localized fibrous plaques, primarily on the tunica albuginea, especially on the dorsal area of the penis. These plaques are the hallmark feature of this condition, resulting in penile curvature, deformity, and painful erections for affected individuals. Although various nonsurgical treatment options exist, their overall effectiveness is limited. As a result, surgical intervention has become the ultimate choice for patients with severe penile curvature deformities and associated erectile dysfunction. Our research team has successfully employed a combined approach involving microscopic electric rotary grinding of the fibrous plaques and the use of tunica vaginalis or bovine pericardium as graft materials for the repairing of the defects of tunica albuginea in the treatment of PD. This approach has consistently yielded highly satisfactory results regarding the restoration of penile shape, with excellent cosmetic results and significantly improved sexual satisfaction. This protocol aims to present a comprehensive surgical management strategy utilizing electric rotary grinding of the plaques and repairing the defects of tunica albuginea by using the tunica vaginalis, which represents an optimal surgical strategy for treating PD.
A pharmaceutical with excellent vehetotropic and antieliptic activities and which can be used in the treatment of psychic and nervous disorders, contains diphenyl phosphinyl acetic acid hydrazide of formula: Ph2P(=O)CH2-C(=O)NHH2 (I) and a filler. (I) are relatively weak tranquilisers, and the main effect is on the centres of vegetative regulation in the hypothalamic and edge structures of the brain, in which the epileptogenic centre in temporal epilepsy is situated. (I) also protects against the group toxicity of phenamine (aphetamine). (I) causes no local irritation and is of low toxicity (LD5o for mice is 293 mg/kg i.v.). Suitable daily doses are 1.0-3.0 g (taken in units of 0.5-1.0g, 2 to 3 times daily). The treatment takes 1 week to 1 1/2 to 2 months and in temporal epilepsy up to 3-5 months.
Sex differences in physiological responses to various stressors, including exercise, have been well documented. However, the specific impact of these differences on exposure to hypoxia, both at rest and during exercise, has remained underexplored. Many studies on the physiological responses to hypoxia have either excluded women or included only a limited number without analyzing sex-related differences. To address this gap, this comprehensive review conducted an extensive literature search to examine changes in physiological functions related to oxygen transport and consumption in hypoxic conditions. The review encompasses various aspects, including ventilatory responses, cardiovascular adjustments, hematological alterations, muscle metabolism shifts, and autonomic function modifications. Furthermore, it delves into the influence of sex hormones, which evolve throughout life, encompassing considerations related to the menstrual cycle and menopause. Among these physiological functions, the ventilatory response to exercise emerges as one of the most sex-sensitive factors that may modify reactions to hypoxia. While no significant sex-based differences were observed in cardiac hemodynamic changes during hypoxia, there is evidence of greater vascular reactivity in women, particularly at rest or when combined with exercise. Consequently, a diffusive mechanism appears to be implicated in sex-related variations in responses to hypoxia. Despite well-established sex disparities in hematological parameters, both acute and chronic hematological responses to hypoxia do not seem to differ significantly between sexes. However, it is important to note that these responses are sensitive to fluctuations in sex hormones, and further investigation is needed to elucidate the impact of the menstrual cycle and menopause on physiological responses to hypoxia.
PURPOSE:An inhibitor against cancer metastasis containing a specific N- acetylneuraminic acid derivative as an active ingredient. CONSTITUTION:An inhibitor against cancer metastasis in various forms, containing a compound shown by the formula as an active ingredient. Especially, when it and a stabilizer are processed into a lyophilized agent, and used as an injection, it shows effectively immediate effects. The compound shown by the formula is made into particles with about several mu, pharmaceutically manufactured, and preferably used as an agent for inhalation. A dose is 10-1,000 mg/person/day in the case of intravenous injection, and 12-140 mg/person/day in the case of inhalation. EFFECT:The compound shown by the formula has an action to inhibit action of sialyltransferase existing on the surface of cancerous cell to change properties of the surface of cancerous cell, has low side effects even if it is used for a long period, and it has low toxicity.
PURPOSE:To obtain a highly safe external cataplasm excellent in releasing characteristics and tack force by providing a substrate with a support layer prepared by dispersing or dissolving a percutaneously absorbable medicament in a tacky gel virtually free from water comprising polyacrylic acid, a crosslinking agent therefor and a polyhydric alcohol. CONSTITUTION:The objective pharmaceutical preparation can be obtained by providing (A) a substrate with (B) a medicament support layer prepared by formulating a percutaneously absorbable medicament (e.g. methyl salicylate, camphor, mequitazine) in a tacky gel virtually free from water essentially comprising polyacrylic acid, a crosslinking agent (e.g. aluminum chloride, aluminum sulfate) and a polyhydric alcohol (e.g. ethylene glycol, glycerin). The present pharmaceutical preparation has excellent tack force, causing no skin irritation and being highly safe. Furthermore, this pharmaceutical preparation has such effects as to enhance its usability through sustainedly releasing the subcutaneously absorbable medicament for a long time.
INTRODUCTION: Early antibiotic discontinuation in clinically suspected ventilator-associated pneumonia (VAP) may lead to infection relapse/recurrence and increase mortality. This study aimed to evaluate the incidence and potential predictors of treatment failure with this approach.
METHODOLOGY: A retrospective observational study was conducted between September 2014 and November 2016 in a mixed intensive care unit. We included clinically suspected VAP patients whose quantitative sputum cultures from endotracheal aspirate were negative, allowing antibiotic discontinuation within 24 hours. Patients were monitored for signs and symptoms of recurrent VAP. Incidence and risk factors for treatment failure, defined as pneumonia recurrence, were determined using univariate logistic regression analysis and receiver operating characteristic (ROC) curves.
RESULTS: Forty-three patients met the inclusion criteria. The incidence of treatment failure among culture-negative VAP following early antibiotic discontinuation was 27.9% (12 patients). There were no significant differences in procalcitonin levels, leukocyte counts or body temperature between the two groups, except for the modified clinical pulmonary infection score (mCPIS) (5.42 ± 2.19 versus 3.9 ± 1.54, p = 0.014). Procalcitonin levels at VAP diagnosis and antibiotic cessation both showed low predictive capacity for treatment failure (AUC 0.56, CI 95% 0.36-0.76 and AUC 0.57, CI 95% 0.37-0.76, respectively). However, combining mCPIS with procalcitonin improved the predictive value for treatment failure (AUC 0.765, CI 95% 0.56-0.96).
CONCLUSIONS: Early antibiotic discontinuation may lead to a high incidence of treatment failure among culture-negative VAP patients. Procalcitonin alone should not guide antibiotic discontinuation decisions while combining mCPIS and procalcitonin enhances predictive accuracy for treatment failure.
BACKGROUND: The average daily gain (ADG) of preweaning calves significantly influences their adult productivity and reproductive performance. Gastrointestinal microbes are known to exert an impact on host phenotypes, including ADG. The aim of this study was to investigate the mechanisms by which gastrointestinal microbiome regulate ADG in preweaning calves and to further validate them by isolating ADG-associated rumen microbes in vitro.
RESULTS: Sixteen Holstein heifer calves were selected from a cohort with 106 calves and divided into higher ADG (HADG; n = 8) and lower ADG (LADG; n = 8) groups. On the day of weaning, samples of rumen contents, hindgut contents, and plasma were collected for rumen metagenomics, rumen metabolomics, hindgut metagenomics, hindgut metabolomics, and plasma metabolomics analyses. Subsequently, rumen contents of preweaning Holstein heifer calves from the same dairy farm were collected to isolate ADG-associated rumen microbes. The results showed that the rumen microbes, including Pyramidobacter sp. C12-8, Pyramidobacter sp. CG50-2, Pyramidobacter porci, unclassified_g_Pyramidobacter, Pyramidobacter piscolens, and Acidaminococcus fermentans, were enriched in the rumen of HADG calves (LDA > 2, P < 0.05). Enrichment of these microbes in HADG calves' rumen promoted carbohydrate degradation and volatile fatty acid production, increasing proportion of butyrate in the rumen and ultimately contributing to higher preweaning ADG in calves (P < 0.05). The presence of active carbohydrate degradation in the rumen was further suggested by the negative correlation of the rumen microbes P. piscolens, P. sp. C12-8 and unclassified_g_Pyramidobacter with the rumen metabolites D-fructose (R <  - 0.50, P < 0.05). Widespread positive correlations were observed between rumen microbes (such as P. piscolens, P. porci, and A. fermentans) and beneficial plasma metabolites (such as 1-pyrroline-5-carboxylic acid and 4-fluoro-L-phenylalanine), which were subsequently positively associated with the growth rate of HADG calves (R > 0.50, P < 0.05). We succeeded in isolating a strain of A. fermentans from the rumen contents of preweaning calves and named it Acidaminococcus fermentans P41. The in vitro cultivation revealed its capability to produce butyrate. In vitro fermentation experiments demonstrated that the addition of A. fermentans P41 significantly increased the proportion of butyrate in the rumen fluid (P < 0.05). These results further validated our findings. The relative abundance of Bifidobacterium pseudolongum in the hindgut of HADG calves was negatively correlated with hindgut 4-hydroxyglucobrassicin levels, which were positively correlated with plasma 4-hydroxyglucobrassicin levels, and plasma 4-hydroxyglucobrassicin levels were positively correlated with ADG (P < 0.05).
CONCLUSIONS: This study's findings unveil that rumen and hindgut microbes play distinctive roles in regulating the preweaning ADG of Holstein heifer calves. Additionally, the successful isolation of A. fermentans P41 not only validated our findings but also provided a valuable strain resource for modulating rumen microbes in preweaning calves. Video Abstract.
A substantial proportion of diabetic patients suffer a debilitating and persistent pain state, known as peripheral painful neuropathy that necessitates improved therapy or antidote. Decursin, a major active ingredient from Angelica gigas Nakai, has been reported to possess antidepressant activity in preclinical studies. As antidepressants have been typically used as standard agents against persistent neuropathic pain, this study aimed to probe the effect of decursin on neuropathic pain associated with streptozotocin-induced type 1 diabetes in male C57BL6J mice. The Hargreaves test and the von Frey test were used to assess pain-like behaviors, shown as heat hyperalgesia and mechanical allodynia respectively. Chronic treatment of diabetic mice with decursin not only ameliorated the established symptoms of heat hyperalgesia and mechanical allodynia, but also arrested the development of these pain states given preemptively at low doses. Although decursin treatment hardly impacted on metabolic disturbance in diabetic mice, it ameliorated exacerbated oxidative stress in pain-associated tissues, improved mitochondrial bioenergetics in dorsal root ganglion neurons, and restored nerve conduction velocity and blood flow in sciatic nerves. Notably, the analgesic actions of decursin were modified by pharmacologically manipulating redox status and mitochondrial bioenergetics. These findings unveil the analgesic activity of decursin, an effect that is causally associated with its bioenergetics-enhancing and antioxidant effects, in mice with type 1 diabetes.
We previously reported that long non-coding RNA (lncRNA) RPLP0P2 is involved in the progression of colorectal cancer (CRC); however, its molecular mechanisms in CRC remain unclear. In this study, we observed that RPLP0P2 was upregulated in CRC tissues and cell lines. Cell viability was measured using the MTT and colony formation assays. Migration and invasion capabilities were monitored by wound healing, transwell, and immunofluorescence assays. The results showed that RPLP0P2 downregulation inhibited cell viability, migration, and invasion capabilities of CRC cells, accompanied by decreased PCNA, N-cadherin, and Vimentin, and increased E-cadherin expression. Using the DIANA online database, miR-129-5p was identified as a downstream target of RPLP0P2. In fact, RPLP0P2 colocalized with miR-129-5p, acting as a miR-129-5p sponge. MiR-129-5p-inhibition almost abrogated the anti-tumor effects induced by RPLP0P2 inhibition in CRC cells. Zinc finger and BTB domain-containing 20 (ZBTB20) was identified as a potential downstream target of miR-129-5p in CRC cells. ZBTB20 overexpression prevented miR-129-5p mimic-mediated anti-tumor effects in CRC cells. A tumor xenograft assay was performed to monitor the role of RPLP0P2 in tumor growth. Of note, in tumor-bearing mice, RPLP0P2-silencing inhibited tumor growth, followed by increased miR-129-5p and decreased ZBTB20 expression. Our results suggest that lncRNA RPLP0P2 functions as an oncogene that promotes CRC cell proliferation and invasion via regulating the miR-129-5p/ZBTB20 axis, thus, it may serve as a candidate target for CRC interventional therapies.
PURPOSE:To obtain a bathing agent having high moisture retaining effect only by the addition of a small amount of a betaine having excellent moisture- retaining action and touch-improving action, giving extremely good touch after use by including the betaine as an active ingredient. CONSTITUTION:This bathing agent contains a betaine expressed by the formula (another name: trimethylglycine, glycine betaine or alkyldimethylbetaine) as an active ingredient. The betaine of the formula is blended in an amount of 0.05-10 pts.wt., preferably 2-5 pts.wt. into this bathing agnet. The bathing agent can contain a skin cleansing agent such as sodium carbonate, a softening agent such as liquid paraffin, an emulsion such as polyoxyethylene lauryl ether and an ingredient having pharmaco dynamic effect such as colloid sulfur, a perfume, a coloring agent, etc., in addition to the essential ingredient. The bathing agent is excellent in moistening feeling and slippery feeling.
The first phase of the work (Year 1) will be to adapt the 6-session therapist-delivered VC-CBT for delivery on an internet-based computer platform. This work will be done using a standard iterative process for developing e-content in partnership with local technology experts experienced in producing engaging and effective e-learning products. Approximately 5 patients will be employed in this phase. The second phase (Years 2 and 3) will be devoted to a single arm pilot trial to test the efficacy of the refined computer-delivered VC-CBT. The investigators will recruit AUD treatment patients with co-occurring anxiety disorder to receive the computer-delivered VC-CBT (50 patients). Participants will complete follow-up assessments one and four months following treatment. Participants will rate user satisfaction and will be evaluated on skill and knowledge acquisition as well as use of the tools in the follow-up period. Success in the proposed work will serve as pilot data in support of a rigorous randomized clinical trial. The proposed work aims to provide an easy and inexpensive computer-delivered version of the VC-CBT that has comparable efficacy to the validated but resource-intensive therapist-delivered version. Achieving this will enable the VC-CBT therapy to benefit more AUD treatment patients and to be more easily studied by other investigators.
Following completion of the initial 8-week treatment, subject's were eligible to participate in the sub-study, VARRM. The total participation time for the VARRM sub-study was approximately 1.5 weeks.
BACKGROUND: Adaptive trials usually require simulations to determine values for design parameters, demonstrate error rates, and establish the sample size. We designed a Bayesian adaptive trial comparing ventilation strategies for patients with acute hypoxemic respiratory failure using simulations. The complexity of the analysis would usually require computationally expensive Markov Chain Monte Carlo methods but this barrier to simulation was overcome using the Integrated Nested Laplace Approximations (INLA) algorithm to provide fast, approximate Bayesian inference.
METHODS: We simulated two-arm Bayesian adaptive trials with equal randomization that stratified participants into two disease severity states. The analysis used a proportional odds model, fit using INLA. Trials were stopped based on pre-specified posterior probability thresholds for superiority or futility, separately for each state. We calculated the type I error and power across 64 scenarios that varied the probability thresholds and the initial minimum sample size before commencing adaptive analyses. Two designs that maintained a type I error below 5%, a power above 80%, and a feasible mean sample size were evaluated further to determine the optimal design.
RESULTS: Power generally increased as the initial sample size and the futility threshold increased. The chosen design had an initial recruitment of 500 and a superiority threshold of 0.9925, and futility threshold of 0.95. It maintained high power and was likely to reach a conclusion before exceeding a feasible sample size.
CONCLUSIONS: We designed a Bayesian adaptive trial to evaluate novel strategies for ventilation using the INLA algorithm to efficiently evaluate a wide range of designs through simulation.